Search

Displaying results 5721 - 5730 of 7283 in total
  1. Drug

    LY2275796

    go.drugbank.com/drugs/DB05165
    Investigational

    LY2275796 is a second-generation antisense anti-cancer drug candidate for clinical development. … LY2275796 targets eukaryotic initiation factor- 4E (eIF-4E), a protein involved in the translation of key growth and survival factors that drive tumor progression, angiogenesis and metastases.

  2. Drug

    APD668

    go.drugbank.com/drugs/DB05166
    Experimental

    APD668 is a novel, highly potent and orally active glucose-dependent insulinotropic receptor (GDIR) agonist intended to more efficiently stimulate insulin release by beta cells in response to elevated

  3. Drug

    AT3022

    go.drugbank.com/drugs/DB05172
    Experimental

    AT3022, the Altea Therapeutics’s fentanyl citrate transdermal patch designed to provide safe and rapid management of moderate to severe chronic pain.

  4. Drug

    LX6171

    go.drugbank.com/drugs/DB05180
    Investigational

    LX6171 is an oral drug candidate that was generated by Lexicon medicinal chemists and is being developed to treat disorders characterized by cognitive impairment, such as Alzheimer's disease, schizophrenia or vascular dementia.

  5. Drug

    AS1409

    go.drugbank.com/drugs/DB05182
    Investigational

    It is developed by Antisoma is in a phase I of clinical trial for the treatment of renal cancer and melanoma. … AS1409 is a genetically engineered fusion protein made up of two distinct components. One is the cytokine IL12, which has anti-cancer activity. The other is an antibody that targets tumours.

  6. Drug

    Olesoxime

    go.drugbank.com/drugs/DB05185
    Investigational

    Olesoxime is a cholesterol-like small molecule that has demonstrated a remarkable neuroprotective profile in a battery of both in vitro and in vivo preclinical models.

  7. Drug

    KD3010

    go.drugbank.com/drugs/DB05188
    Experimental

    KD3010 is a small molecule peroxisome proliferator-activator receptor delta (PPAR Delta) agonist for the treatment of metabolic disorders, including obesity.

  8. Drug

    Sofalcone

    go.drugbank.com/drugs/DB05197
    Experimental

    Sofalcone is a mucosal protective agent that has been reported to inhibit growth of Helicobacter pylori. on adherence, production of vacuolating toxin (VT), and induction of interleukin-8 (IL-8) secretion

  9. Drug

    V24343

    go.drugbank.com/drugs/DB05201
    Investigational

    The anti-obesity drug, V24343, acts by targeting the CB1 receptor in the brain and suppressing a person's appetite.

  10. Drug

    KB001

    go.drugbank.com/drugs/DB05222
    Investigational

    KB001 is a Humaneered™ PEGylated monoclonal antibody fragment for the treatment of life-threatening Pseudomonas aeruginosa infections, a common problem of cystic fibrosis and mechanically ventilated